title: Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.
abstract: This document was prepared by the Safety Pharmacology Subcommittee of the Oligonucleotide Safety Working Group (OSWG), a group of industry and regulatory scientists involved in the development and regulation of therapeutic oligonucleotides. The mission of the Subcommittee was to develop scientific recommendations for the industry regarding the appropriate scope and strategies for safety pharmacology evaluations of oligonucleotides (ONs). These recommendations are the consensus opinion of the Subcommittee and do not necessarily reflect the current expectations of regulatory authorities. 1) Safety pharmacology testing, as described in the International Conference on Harmonisation (ICH) S7 guidance, is as applicable to ONs as it is to small molecule drugs and biotherapeutics. 2) Study design considerations for ONs are similar to those for other classes of drugs. In general, as with other therapeutics, studies should evaluate the drug product administered via the clinical route. Species selection should ideally consider relevance of the model with regard to the endpoints of interest, pharmacological responsiveness, and continuity with the nonclinical development program. 3) Evaluation of potential effects in the core battery (cardiovascular, central nervous, and respiratory systems) is recommended. In general: a. In vitro human ether-a-go-go-related gene (hERG) testing does not provide any specific value and is not warranted. b. Emphasis should be placed on in vivo evaluation of cardiovascular function, typically in nonhuman primates (NHPs). c. Due to the low level of concern, neurologic and respiratory function can be assessed concurrently with cardiovascular safety pharmacology evaluation in NHPs, within repeat-dose toxicity studies, or as stand-alone studies. In the latter case, rodents are most commonly used. 4) Other dedicated safety pharmacology studies, beyond the core battery, may have limited value for ONs. Although ONs can accumulate in the kidney and liver, evaluation of functional changes in these organs, as well as gastrointestinal (GI) and unintended "pro-inflammatory" effects, may be best evaluated during repeat-dose toxicity studies. Broad receptor- or ligand-binding profiling has not historically been informative for most ON subclasses, but may have value for investigative purposes.
authors.affiliation: 1 Berman Consulting , Wayland, Massachusetts.
authors.forename: Cindy L
authors.initials: CL
authors.lastname: Berman
authors.forename: Keri
authors.initials: K
authors.lastname: Cannon
authors.forename: Yi
authors.initials: Y
authors.lastname: Cui
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Kornbrust
authors.forename: Armando
authors.initials: A
authors.lastname: Lagrutta
authors.forename: Sunny Z
authors.initials: SZ
authors.lastname: Sun
authors.forename: Jeff
authors.initials: J
authors.lastname: Tepper
authors.forename: Gareth
authors.initials: G
authors.lastname: Waldron
authors.forename: Husam S
authors.initials: HS
authors.lastname: Younis
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000517:prevention & control; D032921:Consensus; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005767:Gastrointestinal Diseases / Q000517:prevention & control; D006801:Humans; D019636:Neurodegenerative Diseases / Q000517:prevention & control; D009841:Oligonucleotides / Q000493:pharmacokinetics / Q000633:toxicity*; D061214:Patient Safety; D017410:Practice Guidelines as Topic; D012107:Research Design
chemical_list: D009841:Oligonucleotides